Surrozen, Inc.
General ticker "SRZN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $238.0M (TTM average)
Surrozen, Inc. follows the US Stock Market performance with the rate: 20.0%.
Estimated limits based on current volatility of 6.3%: low 22.24$, high 25.21$
Factors to consider:
- Total employees count: 44 (+10.0%) as of 2025
- US accounted for 6.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: History of losses, Clinical trial delays, Manufacturing scale up, Labor/talent shortage/retention, Regulatory and compliance
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.59$, 33.01$]
- 2026-12-31 to 2027-12-31 estimated range: [5.00$, 18.81$]
Financial Metrics affecting the SRZN estimates:
- Negative: with PPE of -0.6 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Investing cash flow per share per price, % of -0.08 <= 2.08
- Negative: -0.37 < Inventory ratio change, % of 0
- Negative: Shareholder equity ratio, % of -190.18 <= 7.04
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term SRZN quotes
Long-term SRZN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $10.65MM | $3.48MM |
| Operating Expenses | $45.78MM | $36.19MM | $45.57MM |
| Operating Income | $-45.78MM | $-25.54MM | $-42.09MM |
| Non-Operating Income | $2.74MM | $-38.02MM | $-199.93MM |
| R&D Expense | $27.23MM | $21.13MM | $29.36MM |
| Income(Loss) | $-43.04MM | $-63.56MM | $-242.03MM |
| Net Income(Loss)* | $-43.04MM | $-63.56MM | $-242.03MM |
| Stockholders Equity | $37.94MM | $-21.38MM | $-187.76MM |
| Assets | $46.08MM | $48.47MM | $98.73MM |
| Operating Cash Flow | $-40.36MM | $-17.63MM | $-30.24MM |
| Capital expenditure | $0.40MM | $0.03MM | $0.13MM |
| Investing Cash Flow | $51.72MM | $-0.03MM | $-0.13MM |
| Financing Cash Flow | $0.28MM | $16.18MM | $85.05MM |
| Earnings Per Share** | $-21.33 | $-21.67 | $-32.37 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.